Licensed Funeral Director & Embalmer, Science and Art enthusiast, fossil collector, rookie investor, resident heckler, etc! Proudly blocked by Keith McCollough.
@GunShow_Trader@brobsubeez I've had a position for 5 yrs as well, as I FOMO'd, but have learned a valuable lesson and am thankful for that mistake, as I'm in a much better place financially, now. May you have as much success, despite your dastardly attitude, which I imagine is of great hindrance. PITIFUL!
@GunShow_Trader Nice! You did have a pair to post it! So proud of you- you're still welcome for the gratuitous educational content. At least you're consistent: your posts are as moronic as you sound. 🤣
Dear $HUM, $UNH, and $CLOV Investors,
Growing buzz in the Medicare Advantage world:
Is Humana quietly integrating AI software from Counterpart Health (a Clover Health subsidiary) to crack the code on medical cost reduction?
CEO Jim Rechtin just dropped a quote that mirrors Counterpart’s own white paper—almost word for word.
30–50% improvement in adherence.
25% reduction in care gaps.
Virtual + in-home hybrid care.
Coincidence? Or strategic alignment?
@GunShow_Trader@brobsubeez I think that falls under enthusiasm, not unrealistic expectations, lil mama...
Oh, and how original of a comment that I DO NOT see posted besides what you typed out in a screenshot, bro. Grow a pair.
You're welcome for the lead on the reality check of Wallstreet AS WELL AS why.
@brobsubeez@GunShow_Trader May I add, that this is another gift of a buying opportunity for us, so quit your belly-aching and buy if you still have the conviction in the company- Mgmt almost always delivers above guidance. Are there opportunity costs? Sure. Do what's best for you and/or move on. Seriously.
@brobsubeez@GunShow_Trader You do NOT want them saying anything about SaaS, so they can get the biggest multiple for the share price, which will be the max benefit for shareholders, as they're legally obligated to do. What are you folks not comprehending about that concept?! Lordt...
@ADT ...and still nothing from your lackadaisical 'service', but that's fine, I'm spreading the word on how you treat your loyal customers as well as finding alternate provider options for my friend. I'm gonna keep posting until y'all call him & resolve the issue to his satisfaction.
@ADT, my elderly friend has had your service 25+ yrs and y'all act like you're doing him a favor when he's ordering batteries that have otherwise always been covered by saying, "this one-time courtesy". He's almost 71, lives in BFE, and needs your service. Y'all best get a grip!
@ADT If anyone ever wonders why this country is, "going to pot," it's mostly due to these large corporations, their lawyers, as well as their sub-par 'customer service' if you can even call it that, with the generic & disingenuous responses you get from blasting them on social media.
@ADT You might as well have a MANAGER from Acct Mgmt call him, or I'm going to continue airing my grievances about your company, here, on X. Trust me, I WILL, despite needing to work in my gardens. Yes, plural. I'll revisit this tonight to see if y'all could be bothered to call him.
@ADT Furthermore, if you're not going to do anything, then, y'all just seem to he playing on X all day: ineffectual as hell. I'll find him a better, more responsive provider, because I'm shocked that you treat loyal, elderly customers like this! It's shameful, for real...
@ADT What the hell good is it to send that info if you're unwilling to call him to, "resolve this."? You haven't resolved a darn thing, putting onus on the customer: super professional of you and just stellar customer service. Smdh.
@ADT Can't get Acct Mgmt to call him, has to call THEM, yet AGAIN, and wait on hold for however long. Ridiculous! His system is literally OBSOLETE and want to charge an inordinate amount of $ for a new, upgraded system. I don't recommend this company and might get puts on their stock.
Wanted to make everyone aware of the awesome platform/ retail terminal and community that ALSTOCKTRADES has masterfully developed! It includes an immense amount of educational info in the form of courses! My affiliate link: https://t.co/ZgaTTFGyTe
One time fee & Lifetime access!
@albertalan@ALSTOCKTRADES The fact that you mention the Dunning-Kreuger effect shows how much of a legend you're about to be! The best advice I can give these folks is to buy a subscription to your platform and to quit being disingenuous! You either learn the easy or the hard way: you choose!
At 15, homeless, coding from MIT courses on borrowed Wi-Fi. At 32, my AI platform has empowered investors to grow their net worth by over $45 million. When the world undervalues you, redefine your worth. Your struggle today is tomorrow’s superpower. 🚀
Dear $CLOV, $ELV, $CNC, $ALHC, $UNH, $MOH, and $HUM Investors,
Everyone knows Tom Lee—Wall Street’s retail investor favorite. He’s backed Tempus AI $TEM, a precision medicine juggernaut at the intersection of AI and diagnostics. But here’s what he hasn’t picked (yet): Clover Health CLOV—and it’s quietly building a game-changing story most are missing.
Clover just launched Counterpart Health, a SaaS platform spun out of Clover Assistant that’s already live with prestigious systems like Duke Connected Care, Iowa Clinic, and Southern Illinois Healthcare. Its AI platform isn’t theory—it’s real-world proven:
✅ Over 1,000 basis points (10%) improvement in medical cost ratio
✅ 18% fewer hospitalizations
✅ 25% fewer readmissions
✅ Already free cash flow positive in 2024
✅ On track for GAAP profitability
While TEM focuses on oncology/genomics with deep AI, CLOV is carving a different but complementary lane: primary care cost reduction at scale. Both are AI-first. Both are tackling the broken economics of American healthcare. But only one is:
📌 Selling a high-margin subscription platform
📌 Targeting Medicare Advantage—one of the biggest slices of U.S. GDP
📌 Aligned with CMS/Medicare’s $trillion+ mandate to fund interoperable AI tools that actually lower costs
I’ve been investing for 14+ years. And if there’s one thing I’ve learned, it’s that proof-of-concept precedes perception. CLOV is early—but it’s already delivering. Once the market—and Tom Lee—see what we see, this stock won’t be $2.50 anymore.
I predict: Tom Lee will eventually add CLOV to his core AI-health picks, because this play sits exactly at the intersection of:
Rising healthcare costs
AI-enabled clinical decision support
Value-based care models
And most importantly: cash-efficient execution
By the time he does, those who followed this thread and did their own due diligence early will be the ones riding the vertical curve of wealth creation.
Healthcare AI isn’t just oncology and genomics—it’s about system-wide cost savings. That’s where Clover is headed.
📌 Save this post. Refer back when CLOV is no longer under the radar.